Home > Signaling Pathways>Angiogenesis>FLT3>Tandutinib (MLN518, CT53518, NSC-726292)
Tandutinib (MLN518, CT53518, NSC-726292)

This product is for research use only, not for human use. We do not sell to patients.

Tandutinib (MLN518, CT53518, NSC-726292)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
500mg$250Check With Us
1g$450Check With Us
5g$675Check With Us

Cat #: V0585 CAS #: 387867-13-2 Purity ≥ 98%

Description: Tandutinib (formerly also known as MLN-518, CT-53518, D06005, NSC726292), a piperazinyl quinazoline, is a novel, potent and selective FLT3 inhibitor/antagonist with potential antitumor activity.

References: Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1(5), 421-432.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)562.7
Molecular FormulaC31H42N6O4
CAS No.387867-13-2
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 5 mg/mL (8.9 mM)r
Water: <1 mg/mLr
Ethanol: 6 mg/mL (10.7 mM)
Solubility In Vivo0.5% methylcellulose: 30 mg/mL
SMILES CodeO=C(N1CCN(C2=C3C=C(OC)C(OCCCN4CCCCC4)=CC3=NC=N2)CC1)NC5=CC=C(OC(C)C)C=C5
SynonymsMLN 518; CT 53518, D06005, NSC726292, MLN-518, MLN0518, MLN 518, MLN518, NSC 726292, CT53518, NSC-726292, CT-53518, D-06005, D 06005, Tandutinib
ProtocolIn VitroTandutinib inhibits cell proliferation of the FLT3-ITD-positive Molm-13 and Molm-14 with an IC50 of 10 nM. And signaling through the MAP kinase and PI3 kinase pathways. In human FLT3-ITD-positive AML cell lines, Tandutinib inhibits FLT3-ITD phosphorylation (IC50 of ~30 nM). As with Erk2, a constitutively high level of Akt phosphorylation is readily detected and is efficiently blocked by pretreatment of the Molm-14 cells with 100-300 nM Tandutinib. Tandutinib (1 μM; 24-96 hours; Molm-14 and THP-1 AML cells) treatment induces apoptosis in FLT3-ITD-positive AML cells. Tandutinib (0-3 μM; 30 minutes; Ba/F3 cells) treatment inhibits IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10-100 nM in Ba/F3 cells expressing different FLT3-ITD mutants.
In VivoTandutinib (60 mg/kg; oral gavage; daily; for 35 days; athymic nude mice) treatment causes a statistically significant increase in survival that was extended on average by 20 days.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM1.7771 mL8.8857 mL17.7715 mL35.5429 mL
5mM0.3554 mL1.7771 mL3.5543 mL7.1086 mL
10mM0.1777 mL0.8886 mL1.7771 mL3.5543 mL
20mM0.0889 mL0.4443 mL0.8886 mL1.7771 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.